• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

原发性免疫调节紊乱与靶向治疗

Primary Immune Regulatory Disorders and Targeted Therapies.

机构信息

Marmara University Faculty of Medicine, Division of Pediatric Allergy and Immunology, İstanbul, Turkey

İstanbul Jeffrey Modell Diagnostic and Research Center for Primary Immunodeficiencies, İstanbul, Turkey

出版信息

Turk J Haematol. 2021 Feb 25;38(1):1-14. doi: 10.4274/tjh.galenos.2021.2020.0724. Epub 2021 Jan 14.

DOI:10.4274/tjh.galenos.2021.2020.0724
PMID:33442967
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7927447/
Abstract

Primary immune regulatory disorders (PIRDs) are a group of diseases belonging to inborn errors of immunity. They usually exhibit lymphoproliferation, autoimmunities, and malignancies, with less susceptibility to recurrent infections. Unlike classical primary immune deficiencies, in autoimmune manifestations, such as cytopenias, enteropathy can be the first symptom of diseases, and they are typically resistant to treatment. Increasing awareness of PIRDs among specialists and a multidisciplinary team approach would provide early diagnosis and treatment that could prevent end-organ damage related to the diseases. In recent years, many PIRDs have been described, and understanding the immunological pathways linked to these disorders provides us an opportunity to use directed therapies for specific molecules, which usually offer better disease control than known classical immunosuppressants. In this review, in light of the most recent literature, we will discuss the common PIRDs and explain their clinical symptoms and recent treatment modalities.

摘要

原发性免疫调节紊乱(PIRDs)是一组属于先天性免疫缺陷的疾病。它们通常表现为淋巴组织增生、自身免疫和恶性肿瘤,对反复感染的敏感性较低。与经典的原发性免疫缺陷不同,在自身免疫表现中,如血细胞减少症,肠病可以是疾病的首发症状,且通常对治疗有抗性。提高专家和多学科团队对 PIRDs 的认识,可以提供早期诊断和治疗,从而预防与疾病相关的终末器官损伤。近年来,已经描述了许多 PIRDs,了解与这些疾病相关的免疫途径为我们提供了使用针对特定分子的靶向治疗的机会,这通常比已知的经典免疫抑制剂提供更好的疾病控制。在这篇综述中,我们将根据最新的文献,讨论常见的 PIRDs,并解释它们的临床症状和最近的治疗方式。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e0b/7927447/d9887327d43e/TJH-38-1-g2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e0b/7927447/4fcf3e6ec303/TJH-38-1-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e0b/7927447/d9887327d43e/TJH-38-1-g2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e0b/7927447/4fcf3e6ec303/TJH-38-1-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e0b/7927447/d9887327d43e/TJH-38-1-g2.jpg

相似文献

1
Primary Immune Regulatory Disorders and Targeted Therapies.原发性免疫调节紊乱与靶向治疗
Turk J Haematol. 2021 Feb 25;38(1):1-14. doi: 10.4274/tjh.galenos.2021.2020.0724. Epub 2021 Jan 14.
2
Immunodeficiency: Overview of primary immune regulatory disorders (PIRDs).免疫缺陷:原发性免疫调节紊乱疾病(PIRDs)概述。
Allergy Asthma Proc. 2024 Sep 1;45(5):332-339. doi: 10.2500/aap.2024.45.240070.
3
Too much of a good thing: a review of primary immune regulatory disorders.过犹不及:原发性免疫调节紊乱综述。
Front Immunol. 2023 Oct 31;14:1279201. doi: 10.3389/fimmu.2023.1279201. eCollection 2023.
4
Primary Immune Regulatory Disorders With an Autoimmune Lymphoproliferative Syndrome-Like Phenotype: Immunologic Evaluation, Early Diagnosis and Management.原发性免疫调节紊乱伴自身免疫性淋巴增生综合征样表型:免疫评估、早期诊断和治疗。
Front Immunol. 2021 Aug 10;12:671755. doi: 10.3389/fimmu.2021.671755. eCollection 2021.
5
Clinical, Immunological, and Genetic Features in Patients with Activated PI3Kδ Syndrome (APDS): a Systematic Review.PI3Kδ 综合征(APDS)患者的临床、免疫学和遗传学特征:系统评价。
Clin Rev Allergy Immunol. 2020 Dec;59(3):323-333. doi: 10.1007/s12016-019-08738-9.
6
Current and Future Therapeutic Approaches for Thymic Stromal Cell Defects.当前和未来的胸基质细胞缺陷治疗方法。
Front Immunol. 2021 Mar 18;12:655354. doi: 10.3389/fimmu.2021.655354. eCollection 2021.
7
Primary immunodeficiency and autoimmunity: A comprehensive review.原发性免疫缺陷病与自身免疫:全面综述。
J Autoimmun. 2019 May;99:52-72. doi: 10.1016/j.jaut.2019.01.011. Epub 2019 Feb 20.
8
Infection and autoinflammation in inborn errors of immunity: brothers in arms.先天性免疫缺陷中的感染与自身炎症:同仇敌忾。
Curr Opin Immunol. 2021 Oct;72:331-339. doi: 10.1016/j.coi.2021.08.004. Epub 2021 Sep 17.
9
IKAROS Family Zinc Finger 1-Associated Diseases in Primary Immunodeficiency Patients.原发性免疫缺陷病患者中 IKAROS 家族锌指蛋白 1 相关疾病
Immunol Allergy Clin North Am. 2020 Aug;40(3):461-470. doi: 10.1016/j.iac.2020.04.004.
10
Primary immune regulatory disorders: a growing universe of immune dysregulation.原发性免疫调节紊乱:一个不断增长的免疫调节紊乱领域。
Curr Opin Allergy Clin Immunol. 2020 Dec;20(6):582-590. doi: 10.1097/ACI.0000000000000689.

引用本文的文献

1
Loss-of-function of lipopolysaccharide-responsive beige-like anchor protein causes inflammatory bowel disease-a case report and literature review.脂多糖反应性米色样锚定蛋白功能丧失导致炎症性肠病——病例报告及文献综述
Transl Pediatr. 2025 Jun 27;14(6):1344-1352. doi: 10.21037/tp-2024-567. Epub 2025 Jun 13.
2
Analysis of Sirolimus Blood Concentration and Influencing Factors in Pediatric Patients: Implications for Individualized Drug Therapy.儿科患者西罗莫司血药浓度及影响因素分析:对个体化药物治疗的启示
Drugs R D. 2025 Mar;25(1):79-88. doi: 10.1007/s40268-025-00506-9. Epub 2025 Apr 11.
3
Primary immune regulatory disorders (PIRD): expanding the mutation spectrum in Turkey and identification of sixteen novel variants.

本文引用的文献

1
Seletalisib for Activated PI3Kδ Syndromes: Open-Label Phase 1b and Extension Studies.用于活化PI3Kδ综合征的西利他昔:开放标签1b期及扩展研究。
J Immunol. 2020 Dec 1;205(11):2979-2987. doi: 10.4049/jimmunol.2000326. Epub 2020 Oct 28.
2
Primary immune regulatory disorders: a growing universe of immune dysregulation.原发性免疫调节紊乱:一个不断增长的免疫调节紊乱领域。
Curr Opin Allergy Clin Immunol. 2020 Dec;20(6):582-590. doi: 10.1097/ACI.0000000000000689.
3
Human STAT1 Gain-of-Function Heterozygous Mutations: Chronic Mucocutaneous Candidiasis and Type I Interferonopathy.
原发性免疫调节紊乱(PIRD):在土耳其扩大突变谱并鉴定出十六种新的变体。
Immunol Res. 2024 Aug;72(4):714-726. doi: 10.1007/s12026-024-09477-6. Epub 2024 Apr 22.
4
Treg in inborn errors of immunity: gaps, knowns and future perspectives.固有免疫缺陷中的调节性 T 细胞:差距、已知和未来展望。
Front Immunol. 2024 Jan 8;14:1278759. doi: 10.3389/fimmu.2023.1278759. eCollection 2023.
5
Genetics of Immune Dysregulation and Cancer Predisposition: Two Sides of the Same Coin.免疫失调与癌症易感性的遗传学:同一枚硬币的两面。
Clin Exp Immunol. 2022 Dec 15;210(2):114-127. doi: 10.1093/cei/uxac089.
人类 STAT1 功能获得性杂合突变:慢性黏膜皮肤念珠菌病和 I 型干扰素病。
J Clin Immunol. 2020 Nov;40(8):1065-1081. doi: 10.1007/s10875-020-00847-x. Epub 2020 Aug 27.
4
Precision Therapy for the Treatment of Primary Immunodysregulatory Diseases.精准治疗原发性免疫失调疾病。
Immunol Allergy Clin North Am. 2020 Aug;40(3):511-526. doi: 10.1016/j.iac.2020.04.001.
5
Human inborn errors of immunity: An expanding universe.人类先天性免疫缺陷:不断扩展的领域。
Sci Immunol. 2020 Jul 10;5(49). doi: 10.1126/sciimmunol.abb1662.
6
Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis.埃马珠单抗治疗原发性噬血细胞性淋巴组织细胞增生症患儿。
N Engl J Med. 2020 May 7;382(19):1811-1822. doi: 10.1056/NEJMoa1911326.
7
Pediatric hemophagocytic lymphohistiocytosis.儿童噬血细胞性淋巴组织细胞增生症。
Blood. 2020 Apr 16;135(16):1332-1343. doi: 10.1182/blood.2019000936.
8
Human Inborn Errors of Immunity: 2019 Update of the IUIS Phenotypical Classification.人类先天性免疫缺陷:2019 年国际免疫学会联合会表型分类更新。
J Clin Immunol. 2020 Jan;40(1):66-81. doi: 10.1007/s10875-020-00758-x. Epub 2020 Feb 11.
9
Human Inborn Errors of Immunity: 2019 Update on the Classification from the International Union of Immunological Societies Expert Committee.人类先天性免疫缺陷:国际免疫学联盟专家委员会 2019 年分类更新。
J Clin Immunol. 2020 Jan;40(1):24-64. doi: 10.1007/s10875-019-00737-x. Epub 2020 Jan 17.
10
Long-term outcome of LRBA deficiency in 76 patients after various treatment modalities as evaluated by the immune deficiency and dysregulation activity (IDDA) score.LRBA 缺陷患者经不同治疗方式后,通过免疫缺陷和失调活动(IDDA)评分评估的长期结果。
J Allergy Clin Immunol. 2020 May;145(5):1452-1463. doi: 10.1016/j.jaci.2019.12.896. Epub 2019 Dec 27.